{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:58:26Z","timestamp":1790805506111,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10067-019-04451-2","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T05:56:31Z","timestamp":1548827791000},"page":"1513-1519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-8541","authenticated-orcid":false,"given":"Janet","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Smylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lyddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"4451_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"4451_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","volume":"30","author":"Y Diesendruck","year":"2017","unstructured":"Diesendruck Y, Benhar I (2017) Novel immune check point inhibiting antibodies in cancer therapy \u2013 opportunities and challenges. Drug Resist Updat 30:39\u201347","journal-title":"Drug Resist Updat"},{"key":"4451_CR3","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 69:1751\u20131763","journal-title":"Arthritis Care Res"},{"key":"4451_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, in collaboration with the National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"4451_CR5","doi-asserted-by":"publisher","unstructured":"Smith MH, Bass AR (2017) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res. \n                    https:\/\/doi.org\/10.1002\/acr.23467","DOI":"10.1002\/acr.23467"},{"key":"4451_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, le D, Bingham CO III (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43\u201350","journal-title":"Ann Rheum Dis"},{"key":"4451_CR7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim ST, Tayar J, Trinh V, Suarez-Almazor M, Garcia S et al (2017) Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 76:2061\u20132064","journal-title":"Ann Rheum Dis"},{"key":"4451_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 5:95. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"4451_CR9","doi-asserted-by":"publisher","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2016-000412","journal-title":"RMD Open"},{"key":"4451_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X (2017) Rheumatoid arthritis and polymyalgia rheumatic occuring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747\u20131750","journal-title":"Ann Rheum Dis"},{"key":"4451_CR11","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794\u20134804. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1000702","journal-title":"J Immunol"},{"key":"4451_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"D Platone","year":"2018","unstructured":"Platone D, Koudriavtseva T (2018) Current and future use of chlorquine and hydroxycloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653\u2013671","journal-title":"Clin Drug Investig"},{"issue":"8","key":"4451_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/0961203312437270","volume":"21","author":"R Willis","year":"2012","unstructured":"Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, Gonz\u00e1lez EB, Dang N, Papalardo E, Liu J, Vil\u00e1 LM, Reveille JD, Alarc\u00f3n GS, Pierangeli SS (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA, a multiethnic US cohort. Lupus 21(8):830\u2013835. \n                    https:\/\/doi.org\/10.1177\/0961203312437270","journal-title":"Lupus"},{"issue":"4","key":"4451_CR14","first-page":"CD000959","volume":"2000","author":"ME Suarez-Almazor","year":"2000","unstructured":"Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P (2000) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000(4):CD000959","journal-title":"Cochrane Database Syst Rev"},{"key":"4451_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2015.12.017","volume":"771","author":"S Pascolo","year":"2016","unstructured":"Pascolo S (2016) Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol 771:139\u2013144","journal-title":"Eur J Pharmacol"},{"key":"4451_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2017.781","volume":"11","author":"C Verbaanderd","year":"2017","unstructured":"Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V et al (2017) Repurposing drugs in oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience 11:1\u201335","journal-title":"Ecancermedicalscience"},{"issue":"Suppl_4","key":"4451_CR17","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, on behalf of the ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl_4):iv119\u2013iv142","journal-title":"Ann Oncol"},{"key":"4451_CR18","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"4451_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T, FHU ACRONIM (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer \u2013 clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393\u2013398","journal-title":"Ann Rheum Dis"},{"key":"4451_CR20","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376:1989\u20131991","journal-title":"N Engl J Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04451-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T19:15:43Z","timestamp":1580325343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04451-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4451"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04451-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Retrospective data were used, and patients were not contacted for this study. Thus, ethics approval was received but individual patient informed consent was not required for this study by our institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}